🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Ono Pharmaceutical clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA and China registers with Ono Pharmaceutical as lead sponsor. Synced 26 Sep 2026
11Current trials
6Recruiting now
13Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Ono Pharmaceutical is the lead sponsor of 11 current clinical trials in our USA and China registers. 6 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Oxaliplatin, Capecitabine and Nivolumab. The most-studied condition is Gastric Cancer.

ClinicalTrials.gov trials by status

  • Recruiting655%
  • Active, closed545%

Trials by phase

  • Phase 2545%
  • Phase 3327%
  • Phase 1218%
  • Observational19%
01

Clinical trials sponsored by Ono Pharmaceutical

11 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ONO-6414 Administered Orally in Healthy Adult Participants and Patients With Active Ulcerative Colitis
NCT07749768 · Ulcerative Colitis (UC)
Phase 1 Recruiting 2026-08 USA
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
NCT06948448 · Colorectal Cancer
Phase 2 Recruiting 2025-11 USA
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
NCT07104032 · ClinicalTrials.gov ↗ · Relapsed/Refractory Primary Central Nervous System Lymphoma
Phase 3 Recruiting 2026-06 USA
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
NCT05079282 · ClinicalTrials.gov ↗ · Relapsed or Refractory T Cell Lymphoma
Phase 1 Recruiting 2021-12 USA
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
NCT07429266 · ClinicalTrials.gov ↗ · Polycythemia Vera
Phase 3 Recruiting 2026-05 USA
A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL)
NCT07169708 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer NSCLC
Observational Recruiting 2026-03 China
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
NCT06256328 · ClinicalTrials.gov ↗ · Gastric Cancer
Phase 2 Active, closed 2024-01 China
A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
NCT05923866 · ClinicalTrials.gov ↗ · Multiple System Atrophy (MSA)
Phase 2 Active, closed 2023-09 USA
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
NCT05144854 · ClinicalTrials.gov ↗ · Gastric Cancer
Phase 3 Active, closed 2021-11 China
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
NCT06881836 · ClinicalTrials.gov ↗ · Alzheimer Disease
Phase 2 Active, closed 2025-04 USA
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
NCT04947319 · ClinicalTrials.gov ↗ · Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
Phase 2 Active, closed 2021-12 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Ono Pharmaceutical trials

13 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Ono Pharmaceutical trials

11 conditions
Gastric Cancer2Ulcerative Colitis (UC)1Colorectal Cancer1Multiple System Atrophy (MSA)1Relapsed/Refractory Primary Central Nervous System Lymphoma1Alzheimer Disease1Relapsed or Refractory T Cell Lymphoma1Polycythemia Vera1Refractory Primary Central Nervous System Lymphoma1Primary CNS Lymphoma1Non Small Cell Lung Cancer NSCLC1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA85
Clinical trials in China31

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Gastric Cancer

SponsorTrials
Fujian Medical University9
Nanfang Hospital, Southern Medical University8
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology6
The First Affiliated Hospital with Nanjing Medical University5
Chongqing Precision Biotech4
RemeGen3
Yunnan Cancer Hospital3
TORL Biotherapeutics2
Merus2
Wuhan University2

Sponsors with the most current trials registered for this condition.

06

Questions about Ono Pharmaceutical trials

How many clinical trials does Ono Pharmaceutical sponsor?

Ono Pharmaceutical is the lead sponsor of 11 current trials on ClinicalTrials.gov in our USA and China registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Ono Pharmaceutical trials recruiting?

Yes. 6 of its 11 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Ono Pharmaceutical testing?

Its current trials name 13 drugs and biologicals as interventions. The most frequent are Oxaliplatin (3), Capecitabine (2), Nivolumab (2), ONO-4578 (2) and Tegafur Gimeracil Oteracil (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.